> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Xeltis raises an additional €20.5m of funding to advance aXess toward FDA approval and US commercial launch
- URL: https://med-techinsights.com/xeltis-raises-an-additional-e20-5m-of-funding-to-advance-axess-toward-fda-approval-and-us-commercial-launch/
- Published: 2026-08-06T08:29:19.000Z
- Updated: 2026-10-23T02:50:48.000Z
- Description: Xeltis has announced that it had raised an additional €20.5m of new funding from new and existing shareholders. Participating investors included the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders, alongside Horizon 3 Healthcare, a new in
- Author: Oliver Johnson
- Tags: Medical Device Manufacturing, News

[**Xeltis**](https://xeltis.com/?ref=med-techinsights.com) has announced that it had raised an additional €20.5m of new funding from new and existing shareholders. Participating investors included the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders, alongside Horizon 3 Healthcare, a new investor who led the round.

Combined with the [€50m secured in 2025 from the European Investment Bank (EIB)](https://med-techinsights.com/2025/12/04/xeltis-secures-50m-from-eib-to-advance-axess-device/) and existing shareholders, this additional financing and the participation of a new lead investor demonstrates strong investor confidence in Xeltis’ strategy and strengthens the company’s ability to execute on its clinical, regulatory and commercial objectives.

The proceeds raised will be used to finalise the ongoing US pivotal trial of aXess, its first-of-its-kind living vascular access solution for hemodialysis, and to prepare for FDA submission and US Go-To- Market. The funding will also enable the European commercial rollout of aXess, the upscaling of the company’s manufacturing capabilities, and the continued advancement of its XABG and XPAD programs in the clinic.

Eliane Schutte, Chief Executive Officer, Xeltis said: “This fundraising not only enables us to bring our groundbreaking vascular access technology to more European patients, as we continue our successful commercial rollout, but also enables us to advance our aXess pivotal trial in the US, prepare for US market launch and continue our other exciting clinical programs, XABG and XPAD. We welcome our new investor Horizon 3 Healthcare and thank them, and our existing investors, for their confidence in Xeltis as we look to bring much-needed alternatives to patients.”

![](https://storage.ghost.io/c/98/19/9819191a-690e-400b-bf27-720adfd33f45/content/images/2026/10/18305-aXess_Transformation-w-Window.jpg)

Image: Xeltis

Matt McNamara, Chief Investment Officer of Horizon 3 Healthcare commented: “The data generated by Xeltis to date has been highly compelling and underscores the potential of aXess to transform the hemodialysis access landscape and improve patient outcomes. We are impressed by the company’s strong execution and rapid progress and are proud to support Xeltis as it advances aXess through US clinical development and European commercialisation, while continuing to expand its broader pipeline of transformative implants.”

Ineke Cazander, Investment Principal, Invest NL added: “Our continued investment in Xeltis reflects the strong progress the company has made in transformative vascular technology. The commercial launch of aXess in Europe marks an important milestone, and we are pleased to support the company’s next phase of commercial expansion and clinical development.”

Hermann Hauser, Board Member, European Innovation Council (EIC) Fund said: “Today’s vascular implants rely on permanent synthetic or biological replacements. Xeltis is pioneering a different approach: enabling implants to gradually transform into the patient’s own living tissue. This shift illustrates how transformative technology is opening new possibilities for patients while reinforcing Europe’s leadership in breakthrough medical innovations. The European Innovation Council is proud to back companies turning this vision into clinical reality.”

The fundraising follows the recent announcement by Xeltis of the European launch of aXess, with the successful treatment of the first commercial patient in Germany. Alongside European commercialisation, Xeltis continues enrollment in its US pivotal trial of aXess, which now exceeds 50% according to the company

.